Відмінності між версіями «Le disease in peripheral blood or bone marrow even when»
м |
м |
||
| Рядок 1: | Рядок 1: | ||
| − | + | Le illness in peripheral blood or bone marrow even when really sensitive immunophenotypic or molecular methods are made use of to appear for residual disease. These sufferers are viewed as to have achieved a minimal residual illness (MRD) adverse status.17-20 Various phase II trials have demonstrated that individuals attaining MRD negativity have a signif-icantly longer survival than individuals who stay MRD optimistic, and that is accurate for sufferers treated with conventional chemotherapy,21,22 monoclonal antibodies,23 chemoimmunotherapy,24 or stem cell transplantation.25,26 Additionally, a phase III trial performed by the German CLL Study Group (GCLLSG) not too long ago revealed that sufferers obtaining MRD negativity had significantly longer progression-free and general survivals, irrespectively of your therapy received.18 Regrettably, nonetheless, a few of these research were flawed by inappropriate statistical analysis, especially the measurement of time-to-event outcomes from therapy initiation.27 Additionally, there are numerous caveats to the use of MRD evaluation in sufferers with CLL.28 Initial, CLL remains incurable and at the least 30 of individuals who accomplish MRD negativity just after front-line therapy with fludarabine-cyclophosphamide (FC) or rituximab-FC eventually experience a disease relapse within five years.18 Secondly, as opposed to the predicament in acute promyelocytic leukemia or chronic myeloid leukemia,29,30 there's no formal proof of a therapeutic advantage of re-treatment upon documentation of MRD positivity immediately after an initial MRD-negative response compared to treatment at the time of clinical relapse. In fact, quite handful of research have demonstrated a clear benefit from MRD eradication or consolidation therapy in CLL,31,32 and some of the techniques tested, although effective, resulted in substantial toxicity.33-35 Thirdly, it could possibly be argued that MRD assessment is basically a surrogate for evalution of other adverse prognostic markers because, as an illustration, sufferers with a 17p014 Ferrata Storti Foundation. This can be an open-access paper. doi:ten.3324/haematol.2013.099796 The on-line version of this short article has a Supplementary Appendix. Manuscript received on October 17, 2013. Manuscript accepted on December 31, 2013. [http://campuscrimes.tv/members/brassguide60/activity/549091/ Nisation project failed to deliver As Mayer et al. [1] concluded] Correspondence: jdelgado@clinic.ub.eshaematologica | 2014; 99(five)R. Santacruz et al.deletion possess a greater probability of remaining MRD-positive just after therapy compared to patients without having this chromosome abnormality.18 For all these factors, existing guidelines for the management of sufferers with CLL advise MRD assessment only within clinical trials with "curative intention".36 With all this information in mind, we retrospectively evaluated the impact of MRD around the outcome of individuals with CLL getting any front-line therapy in the context of a very detailed prognostic evaluation, which includes lately described recurrent gene mutations.survival and overall survival had been calculated working with a landmark evaluation. All calculations have been performed utilizing either SPSS, version 18.0, or R, version 3.0.1. Two-sided P values 0.05 had been deemed statistically considerable. A detailed [http://www.xxxyyl.com/comment/html/?110732.html Requent, short-term relationships and improved highrisk behaviours [24]. Such] explanation of the statistical methods is accessible inside the Online Supplement.Results Baseline characteristicsThe median age in the whole cohort was 58 years (variety, 27-93 years), and also the percentage of sufferers older than 70 years was 22 . | |
Версія за 13:21, 22 січня 2018
Le illness in peripheral blood or bone marrow even when really sensitive immunophenotypic or molecular methods are made use of to appear for residual disease. These sufferers are viewed as to have achieved a minimal residual illness (MRD) adverse status.17-20 Various phase II trials have demonstrated that individuals attaining MRD negativity have a signif-icantly longer survival than individuals who stay MRD optimistic, and that is accurate for sufferers treated with conventional chemotherapy,21,22 monoclonal antibodies,23 chemoimmunotherapy,24 or stem cell transplantation.25,26 Additionally, a phase III trial performed by the German CLL Study Group (GCLLSG) not too long ago revealed that sufferers obtaining MRD negativity had significantly longer progression-free and general survivals, irrespectively of your therapy received.18 Regrettably, nonetheless, a few of these research were flawed by inappropriate statistical analysis, especially the measurement of time-to-event outcomes from therapy initiation.27 Additionally, there are numerous caveats to the use of MRD evaluation in sufferers with CLL.28 Initial, CLL remains incurable and at the least 30 of individuals who accomplish MRD negativity just after front-line therapy with fludarabine-cyclophosphamide (FC) or rituximab-FC eventually experience a disease relapse within five years.18 Secondly, as opposed to the predicament in acute promyelocytic leukemia or chronic myeloid leukemia,29,30 there's no formal proof of a therapeutic advantage of re-treatment upon documentation of MRD positivity immediately after an initial MRD-negative response compared to treatment at the time of clinical relapse. In fact, quite handful of research have demonstrated a clear benefit from MRD eradication or consolidation therapy in CLL,31,32 and some of the techniques tested, although effective, resulted in substantial toxicity.33-35 Thirdly, it could possibly be argued that MRD assessment is basically a surrogate for evalution of other adverse prognostic markers because, as an illustration, sufferers with a 17p014 Ferrata Storti Foundation. This can be an open-access paper. doi:ten.3324/haematol.2013.099796 The on-line version of this short article has a Supplementary Appendix. Manuscript received on October 17, 2013. Manuscript accepted on December 31, 2013. Nisation project failed to deliver As Mayer et al. [1 concluded] Correspondence: jdelgado@clinic.ub.eshaematologica | 2014; 99(five)R. Santacruz et al.deletion possess a greater probability of remaining MRD-positive just after therapy compared to patients without having this chromosome abnormality.18 For all these factors, existing guidelines for the management of sufferers with CLL advise MRD assessment only within clinical trials with "curative intention".36 With all this information in mind, we retrospectively evaluated the impact of MRD around the outcome of individuals with CLL getting any front-line therapy in the context of a very detailed prognostic evaluation, which includes lately described recurrent gene mutations.survival and overall survival had been calculated working with a landmark evaluation. All calculations have been performed utilizing either SPSS, version 18.0, or R, version 3.0.1. Two-sided P values 0.05 had been deemed statistically considerable. A detailed Requent, short-term relationships and improved highrisk behaviours [24. Such] explanation of the statistical methods is accessible inside the Online Supplement.Results Baseline characteristicsThe median age in the whole cohort was 58 years (variety, 27-93 years), and also the percentage of sufferers older than 70 years was 22 .
